|
Study compares three induction immunosuppressants, finds the cheapest one, alemtuzumab, to be noninferior. |
 |
 |
|
EurekAlert: "These are intravenous drugs given at the time of transplant in the operating room or early in the first week after transplant and are intensive immunosuppressants, designed to prevent early rejection," said the study's lead author, Michael Hanaway, M.D., surgeon in the Division of Abdominal Transplantation at UAB. With more than 260 transplants annually, the UAB kidney transplant program is among the busiest in the country. The researchers found that alemtuzumab – a drug originally approved for lymphoma treatment, which costs around $2,000 – worked better than or as well as either basiliximab or antithymocyte globulin, which cost about $4,000 and $10,000, respectively.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
